Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 15/20 | 0.42 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490356 | 0.92 | MEN1 (0.37) | ANO1ANO2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1490349 | 0.91 | PTPN1 (0.39) | ANO1TAS1R3TAS1R1TAS1R2POLB | |
| SCHEMBL1490205 | 0.91 | MEN1 (0.44) | TAS1R3TAS1R1TAS1R2POLBABCB1 | |
| SCHEMBL1490395 | 0.91 | MEN1 (0.44) | ANO1POLBABCB1KDM4E | |
| SCHEMBL1490155 | 0.90 | MEN1 (0.45) | ANO1ABCB1 | |
| SCHEMBL1490501 | 0.89 | TAS1R3 (0.39) | ANO1TAS1R3TAS1R1TAS1R2ACLY | |
| SCHEMBL1490413 | 0.89 | ANO1 (0.46) | ANO1ANO2ACLYKDM4ENPSR1 | |
| SCHEMBL1490327 | 0.88 | NPSR1 (0.42) | ANO1ANO2POLBKDM4ENPSR1 | |
| SCHEMBL1490569 | 0.85 | ANO1 (0.46) | ANO1ANO2ACLYKDM4ENPSR1 | |
| SCHEMBL1490412 | 0.85 | POLB (0.38) | TAS1R3TAS1R1TAS1R2POLBABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8618307-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885ANO2 98/4885TAS1R3 3820/4885 |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885ANO2 98/4885TAS1R3 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.